Syndax Pharmaceuticals Ownership | Who Owns Syndax Pharmaceuticals?
Syndax Pharmaceuticals Ownership Summary
Syndax Pharmaceuticals is owned by 117.83% institutional investors, 1.29% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 12.11% of SNDX shares. Vanguard Health Care Inv is the top mutual fund, with 3.50% of its assets in Syndax Pharmaceuticals shares.
SNDX Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Syndax Pharmaceuticals | 117.83% | 1.29% | -19.12% |
Sector | Healthcare Stocks | 488.17% | 11.08% | -399.26% |
Industry | Biotech Stocks | 306.59% | 11.10% | -217.69% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Blackrock funding, inc. /de | 10.46M | 12.11% | $97.93M |
Kynam capital management, lp | 8.52M | 9.87% | $79.79M |
Blackrock | 7.91M | 9.28% | $162.33M |
Goldman sachs group | 5.95M | 6.97% | $78.67M |
Vanguard group | 4.88M | 5.71% | $64.54M |
Wellington management group llp | 4.23M | 4.96% | $55.98M |
Eversept partners, lp | 4.07M | 4.71% | $38.07M |
State street | 3.62M | 4.25% | $74.37M |
Stempoint capital lp | 2.37M | 2.75% | $22.22M |
Point72 asset management | 2.13M | 2.46% | $19.92M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Kynam capital management, lp | 8.52M | 8.59% | $79.79M |
Stempoint capital lp | 2.37M | 7.13% | $22.22M |
Lion point capital, lp | 55.00K | 3.81% | $727.10K |
Eversept partners, lp | 4.07M | 3.50% | $38.07M |
Sphera funds management | 1.57M | 3.45% | $14.72M |
Aisling capital management lp | 1.32M | 3.43% | $12.33M |
Exome asset management | 318.90K | 3.17% | $4.22M |
Kingdon capital management | 2.10M | 2.65% | $19.67M |
Prosight management, lp | 1.08M | 2.47% | $10.11M |
Ghost tree capital | 350.00K | 2.25% | $7.19M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Goldman sachs group | 5.95M | 0.01% | 4.34M |
Blackrock funding, inc. /de | 10.46M | 0.00% | 1.91M |
Ubs group | 1.03M | 0.00% | 882.38K |
Qube research | 1.67M | 0.02% | 831.07K |
Adage capital partners gp | 1.43M | 0.02% | 800.80K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Avoro capital advisors | - | - | -2.27M |
Orbimed advisors | - | - | -1.93M |
Point72 asset management | 2.13M | 0.04% | -1.88M |
Bvf inc/il | - | - | -1.88M |
Balyasny asset management | 126.14K | 0.00% | -1.69M |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Cubist systematic strategies | 358.07K | 0.03% | 358.07K | $4.73M |
Exome asset management | 318.90K | 3.17% | 318.90K | $4.22M |
Boothbay fund management | 128.84K | 0.02% | 128.84K | $1.21M |
Man group | 121.54K | 0.00% | 121.54K | $1.61M |
Stonepine capital management | 92.90K | 0.85% | 92.90K | $870.01K |
Sold Out
Holder | Change |
---|---|
Tfc financial management | -1.00 |
Nelson, van denburg & campbell wealth management group | -13.00 |
Riggs asset managment | -26.00 |
Svb wealth | -27.00 |
Stephens consulting | -30.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Jun 30, 2025 | 232 | - | 101,730,191 | 1.68% | 117 | 0.86% | 116 | -3.33% | 65 | 1.56% |
Mar 31, 2025 | 233 | 2.19% | 100,944,775 | 2.97% | 117 | 0.90% | 119 | -7.03% | 65 | 10.17% |
Dec 31, 2024 | 216 | -5.68% | 91,955,124 | 3.35% | 107 | 0.99% | 119 | -4.03% | 58 | -1.69% |
Sep 30, 2024 | 225 | 11.39% | 88,858,869 | 1.79% | 104 | 0.99% | 121 | 10.00% | 59 | -3.28% |
Jun 30, 2024 | 200 | 2.56% | 87,296,966 | -3.26% | 102 | 0.66% | 109 | -3.54% | 60 | 11.11% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Vanguard Health Care Inv | 2.99M | 3.50% | - |
Vanguard US Total Market Shares ETF | 2.60M | 3.01% | 4.69K |
Vanguard Total Stock Mkt Idx Inv | 2.56M | 2.98% | -56.87K |
iShares Russell 2000 ETF | 1.99M | 2.31% | -37.80K |
SPDR® S&P Biotech ETF | 1.53M | 1.78% | 37.73K |
Eventide Healthcare & Life Sciences I | 1.18M | 1.37% | - |
Franklin Biotechnology Discv A(acc)USD | 1.02M | 1.18% | - |
Vanguard Institutional Extnd Mkt Idx Tr | 935.83K | 1.09% | -408.69K |
BNP Paribas Health Cr Innovtr Cl Cap | 832.29K | 0.97% | -826.00 |
Fidelity Small Cap Index | 831.63K | 0.97% | -2.46K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Sep 08, 2025 | Metzger Michael A | Chief Executive Officer | Sell | $2.58M |
Aug 14, 2025 | Podlesak Dennis | - | Sell | $272.52K |
Aug 15, 2025 | Podlesak Dennis | - | Sell | $298.41K |
Aug 18, 2025 | Podlesak Dennis | - | Sell | $304.17K |
Jul 16, 2025 | Goldan Keith A. | Chief Financial Officer | Sell | $12.03K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q3 | - | 6 |
2025 Q2 | 4 | - |
2025 Q1 | - | 4 |
2024 Q2 | 1 | - |
2024 Q1 | - | - |
SNDX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools